These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19075871)

  • 1. Development of dry powder inhalers.
    Chougule MB; Padhi BK; Jinturkar KA; Misra A
    Recent Pat Drug Deliv Formul; 2007; 1(1):11-21. PubMed ID: 19075871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1302-19. PubMed ID: 17455364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel alternative methods for the delivery of drugs for the treatment of asthma.
    Chan HK; Chew NY
    Adv Drug Deliv Rev; 2003 Jul; 55(7):793-805. PubMed ID: 12842601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powder inhaler formulation.
    Telko MJ; Hickey AJ
    Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
    Kolanjiyil AV; Kleinstreuer C; Sadikot RT
    Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and evaluation of insulin dry powder for inhalation.
    Mahesh Kumar T; Misra A
    Drug Dev Ind Pharm; 2006 Jul; 32(6):677-86. PubMed ID: 16885123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation techniques for high dose dry powders.
    Brunaugh AD; Smyth HDC
    Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the role of particle morphology in pharmaceutical powder aerosols?
    Chan HK
    Expert Opin Drug Deliv; 2008 Aug; 5(8):909-14. PubMed ID: 18712999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
    Begat P; Morton DA; Staniforth JN; Price R
    Pharm Res; 2004 Oct; 21(10):1826-33. PubMed ID: 15553229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical stability of dry powder inhaler formulations.
    Shetty N; Cipolla D; Park H; Zhou QT
    Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
    [No Abstract]   [Full Text] [Related]  

  • 17. Pulmonary drug delivery by powder aerosols.
    Yang MY; Chan JG; Chan HK
    J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Powder dispersion mechanisms within a dry powder inhaler using microscale particle image velocimetry.
    Kou X; Wereley ST; Heng PW; Chan LW; Carvajal MT
    Int J Pharm; 2016 Dec; 514(2):445-455. PubMed ID: 27497998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.